Sun Pharma-owned subsidiary to acquire Canada's Aquinox Pharma for $8.2 mn

Topics Sun Pharma | acquisition | shares

Taro Pharmaceutical is a US-based subsidiary of Sun Pharmaceutical.

Sun Pharmaceutical Industries on Wednesday said that a wholly-owned subsidiary of Taro Pharmaceutical Industries Ltd will acquire Aquinox Pharmaceuticals (Canada) Inc for $8.2 million.

Taro Pharmaceutical is a US-based subsidiary of Sun Pharmaceutical.

"One of the wholly owned subsidiaries of our subsidiary company, Taro Pharmaceutical Industries Ltd., has agreed to acquire by way of purchase of all outstanding shares of Aquinox Pharmaceuticals (Canada) Inc.," Sun Pharma said in a regulatory filing.

Aquinox Pharmaceuticals is a corporation organised and existing under the laws of the Province of British Columbia that carries on the business of research and development of pharmaceutical products for purposes of their commercialization, it added.

The subsidiary of Taro Pharmaceutical will acquire 100 per cent stake in the company.

The company said that no approvals are required for the acquisition and it is likely to be completed by July 31.

Sun Pharma shares surged on Wednesday on the back of the announcement. At 10.56 a.m., its shares on the BSE were trading at Rs 491.05, higher by Rs 8.55 or 1.77 per cent from its previous close.

 



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel